The 10-second takeaway
For the quarter ended March 31 (Q1), Boston Scientific missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share grew. GAAP earnings per share dropped to a loss.
Gross margins increased, operating margins dropped, net margins dropped.
Boston Scientific booked revenue of $1.76 billion. The 19 analysts polled by S&P Capital IQ expected revenue of $1.79 billion on the same basis. GAAP reported sales were 5.6% lower than the prior-year quarter's $1.87 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.10. The 21 earnings estimates compiled by S&P Capital IQ forecast $0.09 per share. Non-GAAP EPS of $0.10 for Q1 were 11% higher than the prior-year quarter's $0.09 per share. GAAP EPS were -$0.26 for Q1 compared to $0.08 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 64.8%, 100 basis points better than the prior-year quarter. Operating margin was 11.6%, 40 basis points worse than the prior-year quarter. Net margin was -20.1%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $1.79 billion. On the bottom line, the average EPS estimate is $0.09.
Next year's average estimate for revenue is $7.11 billion. The average EPS estimate is $0.41.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 747 members out of 933 rating the stock outperform, and 186 members rating it underperform. Among 178 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 160 give Boston Scientific a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $7.58.
Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Boston Scientific to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Big-Cap Stocks That Are Growing Again
Pfizer, Inc. Microsoft Corp, and Boston Scientific are back on their feet and growing again and that may make now a good time to buy them in portfolios.
These 3 Heart Disease Stocks Are Trouncing the S&P 500 This Year
Returns are sky-high this year for med-tech companies Edwards Lifesciences, Abiomed, and Boston Scientific.
Why Boston Scientific Corporation Rose 15.7% in April
A stellar earnings report pumped up shares of the cardiac device specialist.